{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:18:42Z","timestamp":1781169522502,"version":"3.54.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03140-2","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:20:34Z","timestamp":1763965234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The golden touch: a comprehensive network pharmacology-guided review of synergy between curcumin and PARP inhibitors"],"prefix":"10.1007","volume":"43","author":[{"given":"Elina","family":"Khanehzar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirsajad","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"1","key":"3140_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3140_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","volume":"9","author":"C Mattiuzzi","year":"2019","unstructured":"Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9(4):217\u201322.","journal-title":"J Epidemiol Glob Health"},{"issue":"1","key":"3140_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"16","key":"3140_CR4","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.3390\/cancers14163888","volume":"14","author":"S Boussios","year":"2022","unstructured":"Boussios S, Rassy E, Moschetta M, Ghose A, Adeleke S, Sanchez E, et al. BRCA mutations in ovarian and prostate cancer: bench to bedside. Cancers. 2022;14(16):3888.","journal-title":"Cancers"},{"issue":"3","key":"3140_CR5","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/ijms23031701","volume":"23","author":"W Choi","year":"2022","unstructured":"Choi W, Lee ES. Therapeutic targeting of DNA damage response in cancer. Int J Mol Sci. 2022;23(3):1701.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3140_CR6","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20221713","volume":"42","author":"S Kulkarni","year":"2022","unstructured":"Kulkarni S, Brownlie J, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S. Evolving DNA repair synthetic lethality targets in cancer. Biosci Rep. 2022;42(12):BSR20221713.","journal-title":"Biosci Rep"},{"issue":"11","key":"3140_CR7","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/ijc.33918","volume":"150","author":"C Zong","year":"2022","unstructured":"Zong C, Zhu T, He J, Huang R, Jia R, Shen J. PARP mediated DNA damage response, genomic stability and immune responses. Int J Cancer. 2022;150(11):1745\u201359.","journal-title":"Int J Cancer"},{"key":"3140_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1441222","volume":"14","author":"Y Xie","year":"2024","unstructured":"Xie Y, Xiao D, Li D, Peng M, Peng W, Duan H, et al. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer. Front Oncol. 2024;14:1441222. https:\/\/doi.org\/10.3389\/fonc.2024.1441222.","journal-title":"Front Oncol"},{"issue":"1","key":"3140_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, et al. Clinical approaches to overcome PARP inhibitor resistance. Mol Cancer. 2025;24(1):156.","journal-title":"Mol Cancer"},{"issue":"12","key":"3140_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","volume":"61","author":"MA Bruin","year":"2022","unstructured":"Bruin MA, Sonke GS, Beijnen JH, Huitema AD. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet. 2022;61(12):1649\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"17","key":"3140_CR11","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.3390\/cancers14174162","volume":"14","author":"W Zong","year":"2022","unstructured":"Zong W, Gong Y, Sun W, Li T, Wang Z-Q. PARP1: liaison of chromatin remodeling and transcription. Cancers. 2022;14(17):4162.","journal-title":"Cancers"},{"issue":"5","key":"3140_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054787","volume":"24","author":"JD Puentes-Pardo","year":"2023","unstructured":"Puentes-Pardo JD, Moreno-SanJuan S, Casado J, Escudero-Feliu J, L\u00f3pez-P\u00e9rez D, S\u00e1nchez-Uceta P, et al. PARP-1 expression influences cancer stem cell phenotype in colorectal cancer depending on p53. Int J Mol Sci. 2023;24(5):4787.","journal-title":"Int J Mol Sci"},{"key":"3140_CR13","first-page":"19","volume-title":"PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Arisa O, Peer CJ, Fojo A, Figg WD. PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics. Semin Oncol: Elsevier; 2024. p. 19\u201324."},{"issue":"10","key":"3140_CR14","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3390\/biom14101269","volume":"14","author":"D Bondar","year":"2024","unstructured":"Bondar D, Karpichev Y. Poly (ADP-ribose) polymerase (PARP) inhibitors for cancer therapy: advances, challenges, and future directions. Biomolecules. 2024;14(10):1269.","journal-title":"Biomolecules"},{"issue":"25","key":"3140_CR15","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"AN Tutt","year":"2021","unstructured":"Tutt AN, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405.","journal-title":"N Engl J Med"},{"issue":"22","key":"3140_CR16","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.3390\/cancers14225633","volume":"14","author":"O Franzese","year":"2022","unstructured":"Franzese O, Graziani G. Role of PARP inhibitors in cancer immunotherapy: potential friends to immune activating molecules and foes to immune checkpoints. Cancers. 2022;14(22):5633.","journal-title":"Cancers"},{"issue":"9","key":"3140_CR17","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.cell.2021.03.030","volume":"184","author":"JS Lee","year":"2021","unstructured":"Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell. 2021;184(9):2487\u2013502. e13.","journal-title":"Cell"},{"issue":"12","key":"3140_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773\u201391.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"3140_CR19","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.3390\/cancers14112640","volume":"14","author":"R Abbotts","year":"2022","unstructured":"Abbotts R, Dellomo AJ, Rassool FV. Pharmacologic induction of BRCAness in BRCA-proficient cancers: expanding PARP inhibitor use. Cancers. 2022;14(11):2640.","journal-title":"Cancers"},{"issue":"14","key":"3140_CR20","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.3390\/cancers15143642","volume":"15","author":"S Dilmac","year":"2023","unstructured":"Dilmac S, Ozpolat B. Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches. Cancers. 2023;15(14):3642.","journal-title":"Cancers"},{"issue":"1","key":"3140_CR21","first-page":"9963038","volume":"2021","author":"JB Asiimwe","year":"2021","unstructured":"Asiimwe JB, Nagendrappa PB, Atukunda EC, Kamatenesi MM, Nambozi G, Tolo CU, et al. Prevalence of the use of herbal medicines among patients with cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2021;2021(1):9963038.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"2","key":"3140_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/toxsci\/kfj153","volume":"91","author":"J Cao","year":"2006","unstructured":"Cao J, Jia L, Zhou H-M, Liu Y, Zhong L-F. Mitochondrial and nuclear DNA damage induced by curcumin in human hepatoma G2 cells. Toxicol Sci. 2006;91(2):476\u201383.","journal-title":"Toxicol Sci"},{"issue":"7","key":"3140_CR23","first-page":"3867","volume":"35","author":"C-Y Ting","year":"2015","unstructured":"Ting C-Y, Wang H-E, Yu C-C, Liu H-C, Liu Y-C, Chiang I-T. Curcumin triggers DNA damage and inhibits expression of DNA repair proteins in human lung cancer cells. Anticancer Res. 2015;35(7):3867\u201373.","journal-title":"Anticancer Res"},{"issue":"1","key":"3140_CR24","first-page":"2543504","volume":"2020","author":"R Tong","year":"2020","unstructured":"Tong R, Wu X, Liu Y, Liu Y, Zhou J, Jiang X, et al. Curcumin-induced DNA demethylation in human gastric cancer cells is mediated by the DNA\u2010damage response pathway. Oxidative Med Cell Longev. 2020;2020(1):2543504.","journal-title":"Oxidative Med Cell Longev"},{"issue":"20","key":"3140_CR25","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.1002\/cncr.25414","volume":"116","author":"S Fu","year":"2010","unstructured":"Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer. 2010;116(20):4670\u20136.","journal-title":"Cancer"},{"issue":"23","key":"3140_CR26","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022.","journal-title":"Oncotarget"},{"issue":"13","key":"3140_CR27","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.3390\/cancers16132478","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancers. 2024;16(13):2478.","journal-title":"Cancers"},{"issue":"5","key":"3140_CR28","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/cancers16050932","volume":"16","author":"N Hirschl","year":"2024","unstructured":"Hirschl N, Leveque W, Granitto J, Sammarco V, Fontillas M, Penson RT. PARP inhibitors: strategic use and optimal management in ovarian cancer. Cancers. 2024;16(5):932.","journal-title":"Cancers"},{"issue":"13","key":"3140_CR29","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.3390\/cancers16132479","volume":"16","author":"S Musa","year":"2024","unstructured":"Musa S, Amara N, Selawi A, Wang J, Marchini C, Agbarya A, Mahajna J. Overcoming chemoresistance in cancer: the promise of crizotinib. Cancers. 2024;16(13):2479.","journal-title":"Cancers"},{"issue":"5","key":"3140_CR30","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/biomedicines13051126","volume":"13","author":"S Apelian","year":"2025","unstructured":"Apelian S, Martincuks A, Whittum M, Yasukawa M, Nguy L, Mathyk B, et al. PARP inhibitors in ovarian cancer: resistance mechanisms, clinical evidence, and evolving strategies. Biomedicines. 2025;13(5):1126.","journal-title":"Biomedicines"},{"issue":"38","key":"3140_CR31","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.2174\/0929867330666230112092802","volume":"30","author":"AM Jafari-Nozad","year":"2023","unstructured":"Jafari-Nozad AM, Jafari A, Zangooie A, Behdadfard M, Zangouei AS, Aschner M, et al. Curcumin combats against gastrointestinal cancer: a review of current knowledge regarding epigenetics mechanisms with a focus on DNA methylation. Curr Med Chem. 2023;30(38):4374\u201388.","journal-title":"Curr Med Chem"},{"key":"3140_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061716","author":"BE Bachmeier","year":"2018","unstructured":"Bachmeier BE, Killian PH, Melchart D. The role of curcumin in prevention and management of metastatic disease. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19061716.","journal-title":"Int J Mol Sci"},{"key":"3140_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.934534","author":"DL Pouliquen","year":"2022","unstructured":"Pouliquen DL, Boissard A, Henry C, Coqueret O, Guette C. Curcuminoids as modulators of EMT in invasive cancers: a review of molecular targets with the contribution of malignant mesothelioma studies. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.934534.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3140_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8. https:\/\/doi.org\/10.1038\/s41392-020-0110-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"25","key":"3140_CR35","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.2174\/092986712802884295","volume":"19","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Gu Y, Lee H-M, Hambardjieva E, Vrankov\u00e1 K, Golub M, Johnson L. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem. 2012;19(25):4348\u201358.","journal-title":"Curr Med Chem"},{"issue":"6","key":"3140_CR36","first-page":"1616","volume":"19","author":"M Zahedi","year":"2023","unstructured":"Zahedi M, Izadi HS, Arghidash F, Gumpricht E, Banach M, Sahebkar A. The effect of curcumin on hypoxia in the tumour microenvironment as a regulatory factor in cancer. Arch Med Sci. 2023;19(6):1616.","journal-title":"Arch Med Sci"},{"key":"3140_CR37","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201801_14209","author":"B-Z Zheng","year":"2018","unstructured":"Zheng B-Z, Liu T-D, Chen G, Zhang J-X, Kang X. The effect of curcumin on cell adhesion of human esophageal cancer cell. Eur Rev Med Pharmacol Sci. 2018. https:\/\/doi.org\/10.26355\/eurrev_201801_14209.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"3140_CR38","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.14200","volume":"27","author":"Y Hu","year":"2024","unstructured":"Hu Y, Cheng L, Du S, Wang K, Liu S. Antioxidant curcumin induces oxidative stress to kill tumor cells (Review). Oncol Lett. 2024;27(2):67. https:\/\/doi.org\/10.3892\/ol.2023.14200.","journal-title":"Oncol Lett"},{"issue":"6","key":"3140_CR39","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.3390\/ijms22063168","volume":"22","author":"S Silvestro","year":"2021","unstructured":"Silvestro S, Sindona C, Bramanti P, Mazzon E. A state of the art of antioxidant properties of curcuminoids in neurodegenerative diseases. Int J Mol Sci. 2021;22(6):3168.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3140_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RA. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74\u201388.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3140_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1438040","volume":"14","author":"SF Ameer","year":"2024","unstructured":"Ameer SF, Mohamed MY, Elzubair QA, Sharif EAM, Ibrahim WN. Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment? Front Oncol. 2024;14:1438040.","journal-title":"Front Oncol"},{"issue":"11","key":"3140_CR42","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.2174\/0109298673288542240327112351","volume":"32","author":"V Kumar","year":"2025","unstructured":"Kumar V, Kesharwani R, Patel DK, Verma A, Mehanna MG, Mohammad A, et al. Epigenetic impact of curcumin and thymoquinone on cancer therapeutics. Curr Med Chem. 2025;32(11):2183\u2013201.","journal-title":"Curr Med Chem"},{"issue":"2","key":"3140_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12263-011-0222-1","volume":"6","author":"S Reuter","year":"2011","unstructured":"Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 2011;6(2):93\u2013108. https:\/\/doi.org\/10.1007\/s12263-011-0222-1.","journal-title":"Genes Nutr"},{"key":"3140_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00514","volume":"10","author":"FU Hassan","year":"2019","unstructured":"Hassan FU, Rehman MS, Khan MS, Ali MA, Javed A, Nawaz A, et al. Curcumin as an alternative epigenetic modulator: mechanism of action and potential effects. Front Genet. 2019;10:514. https:\/\/doi.org\/10.3389\/fgene.2019.00514.","journal-title":"Front Genet"},{"issue":"2","key":"3140_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40495-015-0018-x","volume":"1","author":"SS Boyanapalli","year":"2015","unstructured":"Boyanapalli SS, Kong AT. Curcumin, the king of spices: epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. Curr Pharmacol Rep. 2015;1(2):129\u201339. https:\/\/doi.org\/10.1007\/s40495-015-0018-x.","journal-title":"Curr Pharmacol Rep"},{"key":"3140_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122224","volume":"334","author":"F Ravindran","year":"2023","unstructured":"Ravindran F, Mhatre A, Koroth J, Narayan S, Choudhary B. Curcumin modulates cell type-specific miRNA networks to induce cytotoxicity in ovarian cancer cells. Life Sci. 2023;334:122224.","journal-title":"Life Sci"},{"key":"3140_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/112_2016_3","volume":"171","author":"AA Momtazi","year":"2016","unstructured":"Momtazi AA, Shahabipour F, Khatibi S, Johnston TP, Pirro M, Sahebkar A. Curcumin as a MicroRNA regulator in cancer: a review. Rev Physiol Biochem Pharmacol. 2016_;171:1\u201338. https:\/\/doi.org\/10.1007\/112_2016_3.","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"2","key":"3140_CR48","doi-asserted-by":"publisher","first-page":"101042831769168","DOI":"10.1177\/1010428317691680","volume":"39","author":"S Zhou","year":"2017","unstructured":"Zhou S, Zhang S, Shen H, Chen W, Xu H, Chen X, et al. Curcumin inhibits cancer progression through regulating expression of MicroRNAs. Tumour Biol. 2017;39(2):1010428317691680.","journal-title":"Tumour Biol"},{"issue":"6","key":"3140_CR49","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.7150\/ijbs.33710","volume":"15","author":"M Wang","year":"2019","unstructured":"Wang M, Jiang S, Zhou L, Yu F, Ding H, Li P, et al. Potential mechanisms of action of curcumin for cancer prevention: focus on cellular signaling pathways and miRNAs. Int J Biol Sci. 2019;15(6):1200\u201314. https:\/\/doi.org\/10.7150\/ijbs.33710.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3140_CR50","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/s41598-018-20179-6","volume":"8","author":"YA Larasati","year":"2018","unstructured":"Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato J-y. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. 2018;8(1):2039. https:\/\/doi.org\/10.1038\/s41598-018-20179-6.","journal-title":"Sci Rep"},{"key":"3140_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216332","volume":"570","author":"W Wang","year":"2023","unstructured":"Wang W, Li M, Wang L, Chen L, Goh B-C. Curcumin in cancer therapy: exploring molecular mechanisms and overcoming clinical challenges. Cancer Lett. 2023;570:216332.","journal-title":"Cancer Lett"},{"issue":"1","key":"3140_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2015.17","volume":"1","author":"A Moustapha","year":"2015","unstructured":"Moustapha A, P\u00e9r\u00e9tout PA, Rainey NE, Sureau F, Geze M, Petit JM, et al. Curcumin induces crosstalk between autophagy and apoptosis mediated by calcium release from the endoplasmic reticulum, lysosomal destabilization and mitochondrial events. Cell Death Discov. 2015;1(1):15017. https:\/\/doi.org\/10.1038\/cddiscovery.2015.17.","journal-title":"Cell Death Discov"},{"key":"3140_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5787218","volume":"2017","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Bu S. Curcumin induces autophagy, apoptosis, and cell cycle arrest in human pancreatic cancer cells. Evid Based Complement Alternat Med. 2017;2017:5787218. https:\/\/doi.org\/10.1155\/2017\/5787218.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"10","key":"3140_CR54","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.1021\/acs.jmedchem.3c00322","volume":"66","author":"NA Yusoh","year":"2023","unstructured":"Yusoh NA, Tiley PR, James SD, Harun SN, Thomas JA, Saad N, et al. Discovery of ruthenium (II) metallocompound and olaparib synergy for cancer combination therapy. J Med Chem. 2023;66(10):6922\u201337.","journal-title":"J Med Chem"},{"issue":"12","key":"3140_CR55","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1007\/s00432-022-04269-7","volume":"148","author":"S Chatterjee","year":"2022","unstructured":"Chatterjee S, Dhal AK, Paul S, Sinha S, Das B, Dash SR, et al. Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping. J Cancer Res Clin Oncol. 2022;148(12):3521\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3140_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109902","volume":"80","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Sinha S, Molla S, Hembram KC, Kundu CN. PARP inhibitor veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: role of nitric oxide (NO). Cell Signal. 2021;80:109902.","journal-title":"Cell Signal"},{"key":"3140_CR57","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s12253-019-00768-0","volume":"26","author":"S Molla","year":"2020","unstructured":"Molla S, Hembram KC, Chatterjee S, Nayak D, Sethy C, Pradhan R, Kundu CN. PARP inhibitor olaparib enhances the apoptotic potentiality of curcumin by increasing the DNA damage in oral cancer cells through inhibition of BER cascade. Pathol Oncol Res. 2020;26:2091\u2013103.","journal-title":"Pathol Oncol Res"},{"key":"3140_CR58","doi-asserted-by":"publisher","first-page":"103157","DOI":"10.1016\/j.dnarep.2021.103157","volume":"105","author":"S Molla","year":"2021","unstructured":"Molla S, Chatterjee S, Sethy C, Sinha S, Kundu CN. Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly. DNA Repair. 2021;105:103157.","journal-title":"DNA Repair"},{"key":"3140_CR59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.biopha.2017.09.078","volume":"97","author":"Q Zhao","year":"2018","unstructured":"Zhao Q, Guan J, Qin Y, Ren P, Zhang Z, Lv J, et al. Curcumin sensitizes lymphoma cells to DNA damage agents through regulating Rad51-dependent homologous recombination. Biomed Pharmacother. 2018;97:115\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"3140_CR60","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jnutbio.2015.07.015","volume":"26","author":"YE Choi","year":"2015","unstructured":"Choi YE, Park E. Curcumin enhances poly (ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells. J Nutr Biochem. 2015;26(12):1442\u20137.","journal-title":"J Nutr Biochem"},{"issue":"11","key":"3140_CR61","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1093\/carcin\/bgt240","volume":"34","author":"H Ogiwara","year":"2013","unstructured":"Ogiwara H, Ui A, Shiotani B, Zou L, Yasui A, Kohno T. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. Carcinogenesis. 2013;34(11):2486\u201397.","journal-title":"Carcinogenesis"},{"issue":"1","key":"3140_CR62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12859-015-0611-3","volume":"16","author":"H Heberle","year":"2015","unstructured":"Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics. 2015;16(1):169.","journal-title":"BMC Bioinformatics"},{"issue":"10","key":"3140_CR63","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/pharmaceutics13101715","volume":"13","author":"R Tabanelli","year":"2021","unstructured":"Tabanelli R, Brogi S, Calderone V. Improving curcumin bioavailability: current strategies and future perspectives. Pharmaceutics. 2021;13(10):1715.","journal-title":"Pharmaceutics"},{"key":"3140_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/nu11092147","author":"M Dei Cas","year":"2019","unstructured":"Dei Cas M, Ghidoni R. Dietary curcumin: correlation between bioavailability and health potential. Nutrients. 2019. https:\/\/doi.org\/10.3390\/nu11092147.","journal-title":"Nutrients"},{"issue":"4","key":"3140_CR65","doi-asserted-by":"publisher","DOI":"10.1177\/15593258231203585","volume":"21","author":"G Xi","year":"2023","unstructured":"Xi G, Dong Q, Yang B, Jiao D, Khan S. Curcumin\u2019s dose-dependent attenuation of gastric cancer cell progression via the PI3K pathway blockade. Dose Response. 2023;21(4):15593258231203585. https:\/\/doi.org\/10.1177\/15593258231203585.","journal-title":"Dose Response"},{"issue":"3","key":"3140_CR66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/antiox13030331","volume":"13","author":"C Bertoncini-Silva","year":"2024","unstructured":"Bertoncini-Silva C, Vlad A, Ricciarelli R, Giacomo Fassini P, Suen VMM, Zingg J-M. Enhancing the bioavailability and bioactivity of curcumin for disease prevention and treatment. Antioxidants. 2024;13(3):331.","journal-title":"Antioxidants"},{"issue":"6","key":"3140_CR67","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1002\/ptr.8119","volume":"38","author":"S Azarkar","year":"2024","unstructured":"Azarkar S, Abedi M, Lavasani ASO, Ammameh AH, Goharipanah F, Baloochi K, et al. Curcumin as a natural potential drug candidate against important zoonotic viruses and prions: a narrative review. Phytother Res. 2024;38(6):3080\u2013121.","journal-title":"Phytother Res"},{"issue":"6","key":"3140_CR68","doi-asserted-by":"publisher","first-page":"112575","DOI":"10.1016\/j.isci.2025.112575","volume":"28","author":"MA Kroon","year":"2025","unstructured":"Kroon MA, van Laarhoven HW, Swart EL, van Tellingen O, Kemper EM. A Pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability. iScience. 2025;28(6):112575","journal-title":"iScience"},{"key":"3140_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17010114","author":"H Wahnou","year":"2025","unstructured":"Wahnou H, El Kebbaj R, Liagre B, Sol V, Limami Y, Duval RE. Curcumin-based nanoparticles: advancements and challenges in tumor therapy. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17010114.","journal-title":"Pharmaceutics"},{"key":"3140_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114758","volume":"163","author":"P Dytrych","year":"2023","unstructured":"Dytrych P, Kej\u00edk Z, Hajduch J, Kapl\u00e1nek R, Vesel\u00e1 K, Ku\u010dnirov\u00e1 K, et al. Therapeutic potential and limitations of curcumin as antimetastatic agent. Biomed Pharmacother. 2023;163:114758.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"3140_CR71","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1002\/ptr.7121","volume":"35","author":"M Bhatia","year":"2021","unstructured":"Bhatia M, Bhalerao M, Cruz-Martins N, Kumar D. Curcumin and cancer biology: focusing regulatory effects in different signalling pathways. Phytother Res. 2021;35(9):4913\u201329.","journal-title":"Phytother Res"},{"key":"3140_CR72","doi-asserted-by":"publisher","first-page":"1265178","DOI":"10.3389\/fphar.2023.1265178","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Chen Y, Wang L, Liu Q, Yang S, Wang C. Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. Front Pharmacol. 2023;14:1265178.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3140_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00228-024-03764-9","volume":"81","author":"LC Gutsche","year":"2025","unstructured":"Gutsche LC, D\u00f6rfler J, H\u00fcbner J. Curcumin as a complementary treatment in oncological therapy: a systematic review. Eur J Clin Pharmacol. 2025;81(1):1\u201333.","journal-title":"Eur J Clin Pharmacol"},{"key":"3140_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1560729","volume":"16","author":"PdPG Amatto","year":"2025","unstructured":"Amatto PdPG, Chaves L, Fran\u00e7a SdC, Carvalho JCT, Carmona F, Pereira AMS. Efficacy of different pharmaceutical forms of Curcuma longa or curcumin in reducing oral mucositis severity and incidence in cancer patients: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1560729.","journal-title":"Front Pharmacol"},{"issue":"9","key":"3140_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115434","volume":"28","author":"S Lin","year":"2020","unstructured":"Lin S, Zhang L, Zhang X, Yu Z, Huang X, Xu J, et al. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities. Bioorg Med Chem. 2020;28(9):115434.","journal-title":"Bioorg Med Chem"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03140-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03140-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03140-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:03:01Z","timestamp":1769490181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03140-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3140"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03140-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work, the authors used DeepSeek-V3 (https:\/\/chat.deepseek.com) to assist with grammatical checks and readability enhancement. After using this website, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"20"}}